Stock Price, News, Quote and Profile of KEZAR LIFE SCIENCES INC(NASDAQ:KZR) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

KEZAR LIFE SCIENCES INC

NASDAQ:KZR (5/3/2024, 7:02:43 PM)

After market: 0.833 -0.02 (-2.85%)

0.8574

+0 (+0.32%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap62.42M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company is headquartered in South San Francisco, California and currently employs 84 full-time employees. The company went IPO on 2018-06-21. The firm's product portfolio includes zetomipzomib and KZR-261. The zetomipzomib is a selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib trial in patients with systemic lupus erythematosus (SLE). This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well as to explore preliminary anti-tumor activity. The Company’s drug development programs that harness different master regulators of cellular function, which include the immunoproteasome and the Sec61 translocon. Its principal operations are in South San Francisco, California.